Global Coalition for Adaptive Research and GBM AGILE Partners Ring the Nasdaq Stock Market Closing Bell

Global Coalition for Adaptive Research (GCAR, GCAResearch.org), a 501(c)(3) non-profit global research organization, together with their patient/advocacy and pharma/biotech partners, visits the Nasdaq MarketSite in Times Square to highlight National Brain Tumor Awareness Month and an innovative, global brain tumor trial called GBM AGILE. GBM AGILE is a multi-stakeholder adaptive platform trial for patients with glioblastoma (GBM) – the deadliest of malignant primary brain tumors. GBM accounts for 48% of all primary malignant brain cancers and has a median survival rate of less than 15 months, with only 3 treatments approved in the last 40 years. GCAR is joined by their GBM AGILE partners: Bayer, Kazia Therapeutics, Kintara Therapeutics, Vigeo Therapeutics, Biohaven, Polaris Pharmaceuticals, National Brain Tumor Society, National Foundation for Cancer Research, Asian Fund for Cancer Research, and Cure Brain Cancer Foundation. In honor of the occasion, Dr. Meredith Buxton, CEO & President of GCAR, and Mr. Robert Hoffman, President, CEO & Chairman of Kintara Therapeutics, a GBM AGILE industry partner, ring the Closing Bell alongside patients, caregivers, and physicians united to: Raise awareness of the critical, unmet need of new treatment options for patients with brain tumors and the importance of clinical research participation Spotlight the need for investment to fund new treatment options and advance patient care Emphasize the value of innovative trials like GBM AGILE to accelerate drug development through a more cost-effective and rapid path to market approval Each year, approximately 300,000 people worldwide are diagnosed with primary brain tumors. May is National Brain Tumor Awareness Month, a time to support and magnify the voice of the brain tumor community and draw attention to the critical unmet need for better treatment options.